Essai clinique
Récupéré
Publication
clinicaltrials.gov
ACADIA Pharmaceuticals Inc.
(2022).
Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder.
ClinicalTrials.gov.
ACADIA Pharmaceuticals Inc..
- Date de publication
-
09/08/2022
- Identifiant
-
NCT05523895
- Auteurs
-
ACADIA Pharmaceuticals Inc.
- Source
- ClinicalTrials.gov
- Type de référence
- clinical_trial
- Éditeur
- ACADIA Pharmaceuticals Inc.
- Source de métadonnées
- clinicaltrials.gov
Résumé
6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in children and adolescents (aged 5 to17 years) with autism spectrum disorder (ASD) with irritability, agitation, or self-injurious behaviors to study the efficacy and safety of pimavanserin